AddLife AB has made changes to its Group Management Team, with Martin Almgren stepping down as CFO to become Head of the Medtech business area. Martin succeeds Ove Sandin, who will take over the role of Senior Advisor. Christina Rubenhag has been recruited as the new CFO and will join during the second quarter of 2022. Ove Sandin has on his own initiative chosen to leave the role of Business Area Manager for Medtech and transfer to the role of Senior Advisor. Ove Sandin has been a member of Group Management since 2019 and has prior to that been active in several roles within the Group. Martin Almgren takes over as Business Area Manager for Medtech now but will continue as CFO until Christina Rubenhag joins the Group. Martin Almgren has served as AddLife CFO since 2015 and has played an important role in AddLife's development as an independent listed company. Christina Rubenhag has solid financial experience at life science companies and is currently CFO at the listed Boule Diagnostics. This management change exemplifies AddLife's values and corporate culture of encouraging and supporting employees and leaders to broaden their skills by taking on new and developing roles.
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
ADDLIFE AB 
